Jonathan Edwards

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Source: phoenixrising.me

Professor Jonathan Edwards is an Emeritus Professor of Connective Tissue Medicine at University College London (UCL) in the UK. Professor Edwards was instrumental in the discovery of the use of B-cell depletion therapy (Rituximab) to treat rheumatoid arthritis.[1]

B-cell Depletion ME/CFS Research[edit | edit source]

Professor Edwards became interested in the possible use of Rituximab to treat ME/CFS after attending the Invest in ME Conference in May 2013 and subsequently agreed to advise on and lead the effort.[2]

Phoenix Rising[edit | edit source]

Professor Edwards is on the board of directors of the online patient community Phoenix Rising.[3] He is active in its online forums.[4]

Open Letter to The Lancet[edit | edit source]

Two open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. The first, written in 2015, was sign by Dr. Edwards and 5 of his colleagues. In 2016, thirty-six additional colleagues in the ME/CFS field, signed the second letter.

Publications Related to ME/CFS[edit | edit source]

Talks & Interviews[edit | edit source]

See Also[edit | edit source]

References[edit | edit source]

  1. B cell depletion: an effective therapy in rheumatoid arthritis
  2. UK rituximab Trial - Statements By Professor Jonathan Edwards and Invest in ME - July 2013
  3. Phoenix Rising Adds Two New Board Members
  4. Jonathan Edwards
  5. Edwards, J.C.W., McGarth, S., Baldwin, A., Livingstone, M., Kewley, A. (2016). The biological challenge of myalgic encephalomyelitis/chronic fatigue syndrome: a solvable problem. Fatigue: Biomedicine, Health & Behavior 4 (2):63-69. doi: 10.1080/21641846.2016.1160598